인쇄하기
취소

Jeil Pharmaceutical’s new diabetes type I drug development selected as MOHW’s project

Published: 2017-09-26 16:42:29
Updated: 2017-09-26 16:42:29

‘JP -2266,’ a new oral diabetes type I drug being developed by Jeil Pharmaceutical(CEO/President Seok-Jae Sung), was selected as the Ministry of Health and Welfare’s high-tech medical technology development(new drug development support) project.

As being selected as a new supported project, ‘JP-2266’ will be completed in a non-clinical GLP toxicity study for 2 years and is expected to be devel...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.